CP and hepatocellular carcinoma: There were no differences between ITT SVR rates regarding HCV genotype (p=0.453), CP score (p=1.0), previous HCV treatment (p=0.503), presence of ascites (p=0.496), hepatic encephalopathy (p=0.198), previous portal hypertension related bleeding (p=1.0), or previous HCC (p=1.0).